NASDAQ:IMMP Prima BioMed (IMMP) Stock Price, News & Analysis $3.42 +0.17 (+5.23%) Closing price 04:00 PM EasternExtended Trading$3.40 -0.02 (-0.70%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainSEC Filings About Prima BioMed Stock (NASDAQ:IMMP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Prima BioMed alerts:Sign Up Key Stats Today's Range$3.31▼$3.5750-Day Range$2.69▼$7.4752-Week Range$2.66▼$70.60Volume81,113 shsAverage Volume35,367 shsMarket Capitalization$25.21 millionP/E RatioN/ADividend YieldN/APrice Target$110.00Consensus RatingHold Company Overview Prima BioMed was an Australian biotechnology company focused on developing immunotherapies for cancer. It changed its name to Immutep Limited in 2017 and continued its work in immuno-oncology under that name. The company’s research has centered on LAG-3, an immune-system protein. Its lead candidate, eftilagimod alpha (efti, formerly IMP321), is a soluble LAG-3 fusion protein designed to stimulate immune responses and has been studied as a treatment for cancer, including in combination with other therapies. Immutep has also pursued other LAG-3-based candidates, including an approach being investigated for autoimmune diseases. The company’s development programs have involved clinical research conducted with international partners.AI Generated. May Contain Errors. Read More Prima BioMed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreIMMP MarketRank™: 2.154426904595 of 5 starsPrima BioMed scored higher than 43% of companies evaluated by MarketBeat, and ranked 589th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingPrima BioMed has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 1 strong buy rating, 1 buy rating, 2 hold ratings, and 1 sell rating.Upside PotentialPrima BioMed has a consensus price target of $110.00, representing about 3,116.4% upside from its current price of $3.42.Amount of Analyst CoveragePrima BioMed has only been the subject of 2 research reports in the past 90 days.Read more about Prima BioMed's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioPrima BioMed has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.46% of the float of Prima BioMed has been sold short.Short Interest Ratio / Days to CoverPrima BioMed has a short interest ratio ("days to cover") of 2.38, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Prima BioMed has recently decreased by 1.14%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPrima BioMed does not currently pay a dividend.Dividend GrowthPrima BioMed does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Prima BioMed this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for IMMP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Prima BioMed to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Prima BioMed insiders have not sold or bought any company stock.Percentage Held by Insiders3.07% of the stock of Prima BioMed is held by insiders.Percentage Held by Institutions2.32% of the stock of Prima BioMed is held by institutions.Read more about Prima BioMed's insider trading history. Receive IMMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prima BioMed and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMMP Stock News HeadlinesImmutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue SarcomaNovember 18 at 7:12 PM | globenewswire.comImmutep Further Expands United States Patent Estate for Efti-Based Combination TherapiesNovember 10, 2026 | globenewswire.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 19 at 1:00 AM | Behind the Markets (Ad)Immutep Announces Release of CTOS 2026 Abstract Reporting First Survival Data from EFTISARC-NEONovember 10, 2026 | globenewswire.comIMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune ResponsesNovember 8, 2026 | globenewswire.comImmutep Receives ~A$0.86 Million R&D Tax IncentiveSeptember 30, 2026 | globenewswire.comImmutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004July 13, 2026 | globenewswire.comImmutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMPJuly 6, 2026 | prnewswire.comSee More Headlines IMMP Stock Analysis - Frequently Asked Questions How have IMMP shares performed this year? Prima BioMed's stock was trading at $57.20 at the beginning of 2026. Since then, IMMP stock has decreased by 94.0% and is now trading at $3.42. How were Prima BioMed's earnings last quarter? Prima BioMed Ltd (NASDAQ:IMMP) posted its quarterly earnings results on Thursday, July, 30th. The biotechnology company reported ($1.80) earnings per share for the quarter. The biotechnology company earned $3.68 million during the quarter. When did Prima BioMed's stock split? Prima BioMed's stock reverse split on Monday, September 28th 2026.A 1-20 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, September 27th 2026. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Prima BioMed? Shares of IMMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Prima BioMed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Prima BioMed investors own include Novavax (NVAX), NVIDIA (NVDA), Pfizer (PFE), Vaxart (VXRT), Inovio Pharmaceuticals (INO), BioCryst Pharmaceuticals (BCRX) and BioLineRx (BLRX). Company Calendar Last Earnings7/30/2026Today11/19/2026AGM 202611/26/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 IMMP's financial health is in the Red zone, according to TradeSmith. IMMP has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IMMP CIK1506184 Webwww.immutep.com Phone(128) 315-7003Fax61-2-8569-1880Employees53Year Founded2001Price Target and Rating Average Price Target for Prima BioMed$110.00 High Price Target$200.00 Low Price Target$20.00 Potential Upside/Downside+3,116.4%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio5.69 Quick Ratio5.69 Sales & Book Value Annual Sales$16.40 million Price / Sales1.54 Cash FlowN/A Price / Cash FlowN/A Book Value$5.67 per share Price / Book0.60Miscellaneous Outstanding Shares7,370,000Free Float7,145,000Market Cap$25.21 million OptionableOptionable Beta2.33 Social Links 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NASDAQ:IMMP) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prima BioMed Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Prima BioMed With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.